Business context and reporting period
XORTX Therapeutics Inc. is a clinical-stage biotechnology company developing therapies for kidney disease. This Form 20-F reports the audited fiscal year ended December 31, 2023, with comparative 2022 and 2021 results. The company reports under IFRS in U.S. dollars; its functional currency changed from Canadian dollars to U.S. dollars effective January 1, 2023, and prior-period presentation was retrospectively translated. This is an annual report, not a standalone 2023 fourth-quarter report.
Its lead programs are XRx-008 (proprietary oxypurinol formulation for autosomal dominant polycystic kidney disease, or ADPKD), XRx-101 (acute kidney injury associated with respiratory virus infection), and XRx-225 (type 2 diabetic nephropathy). No product is approved for sale, and the company reported no product revenue.
Financial performance and position
| Metric (U.S. dollars, except per-share data) | 2023 | 2022 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $2.42 million | $6.76 million |
| Net loss | $2.16 million | $7.72 million |
| Basic and diluted loss per share | $1.09 | $5.22 |
| Net cash used in operating activities | $6.58 million | $8.96 million |
| Cash and cash equivalents at year-end | $3.45 million | $10.43 million |
| Total assets | $5.47 million | $12.37 million |
| Total liabilities | $0.83 million | $5.38 million |
| Shareholders’ equity | $4.64 million | $7.00 million |
2023 operating cash outflow was partly offset by $0.30 million of net financing cash flow after share-issuance costs; the company received no material proceeds from equity instruments in 2023. Cash declined by $6.99 million during the year. Current assets were $4.07 million and current liabilities $0.29 million, implying working capital of approximately $3.77 million. The filing identifies no significant conventional borrowing; liabilities included a $0.53 million derivative warrant liability and an $11,510 lease obligation, with $0.28 million of accounts payable and accrued liabilities.
Gross margin is not applicable because the company had no product sales. Net loss improved substantially year over year, but the result included a $3.64 million non-cash gain from remeasurement of derivative warrant liabilities and $0.25 million of interest income. The company’s loss before these other items was $6.05 million, versus $10.29 million in 2022. The filing reports an accumulated deficit of $17.85 million at year-end.
Material changes versus the prior comparable period
- R&D expense fell to $2.42 million from $6.76 million, while operating cash use also decreased. The filing does not attribute the full reduction to specific program or timing factors in the financial statements.
- Year-end cash declined about 67% from 2022; shareholders’ equity also decreased.
- The 2023 loss was lower than 2022, in part because of non-cash warrant-liability fair-value gains in both years. The derivative warrant liability fell to $0.53 million from $3.85 million.
- A one-for-nine share consolidation took effect in November 2023. The company reported 1,998,848 shares outstanding at December 31, 2023; per-share and share-count comparisons in the financial statements reflect the consolidation.
- The company changed its functional and presentation currency to U.S. dollars in 2023. Management applied the functional-currency change prospectively and translated comparative presentation retrospectively.
Outlook, risks, contingencies and unusual items
- Funding: Management expects substantial additional financing to advance development and states that funding may not be available on acceptable terms or at all. Failure to raise capital could require delaying, reducing or ending programs. No precise cash runway estimate is provided in the filing text.
- Development and regulatory outlook: XRx-008 received U.S. Orphan Drug Designation in 2023. Management reports FDA discussions on trial endpoints and potential accelerated-approval eligibility, but approval and the planned Phase 3 trial remain uncertain and subject to further regulatory requirements. Oxypurinol was previously reviewed by the FDA in a third-party application but was not approved.
- Pipeline stage: XRx-008 is being prepared for a Phase 3 registration trial; XRx-101 requires further bridging and regulatory discussions; XRx-225 remains in nonclinical development. No clinical or commercial success is assured.
- Post-year-end financing: In February and March 2024, the company closed two tranches of a unit offering for stated aggregate gross proceeds of CAD $2.70 million, before finder’s fees and other costs. Units included shares and two-year warrants exercisable at $4.50 per share. Separately, a November 2023 ATM agreement permits sales of up to $3.70 million of common shares, subject to a 3% commission; the filing does not state that the full ATM amount was raised.
- Warrants and dilution: The company proposed and later obtained TSXV approval to reduce exercise prices on certain outstanding warrants to $5.00, with an acceleration-expiry feature if specified share-price thresholds are met. Exercise could provide cash but would dilute existing shareholders. The filing’s warrant counts and terms should be checked against subsequent amendments and exercises.
- Other risks: The company relies on third parties for clinical trials and manufacturing, has no internal sales organization, and faces clinical, safety, intellectual-property, competition, reimbursement, foreign-exchange and cybersecurity risks. Management believes disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not provide an ICFR attestation because the company is an emerging growth company.
- Audit and tax: The auditor issued an unqualified IFRS opinion and reported no critical audit matters. The company believes it was a passive foreign investment company (PFIC) for 2023 and says it may remain one in 2024, presenting potential adverse U.S. tax consequences for U.S. holders.
Most important facts for investors to verify
- Cash balance and actual operating cash burn after December 31, 2023, including the net proceeds and subsequent use of the 2024 offering and any ATM sales.
- Current share count and fully diluted capitalization, including outstanding warrants, options, amended exercise prices, and potential acceleration provisions.
- FDA feedback, agreed trial design and endpoints, funding, and timing for the XRx-008 Phase 3 program and any accelerated-approval pathway; separately, the development plan for XRx-101.
- Whether operating-cost reductions reflect sustainable spending levels or deferred clinical and development work.
- PFIC status and U.S. tax reporting implications, with advice from a tax professional where relevant.